Beta Synuclein (Sncb) Biomarker is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Beta-Synuclein (SNCB) is a member of the synuclein family of proteins that includes alpha-synuclein and gamma-synuclein. While alpha-synuclein is famously associated with Parkinson's disease and other synucleinopathies, beta-synuclein plays a protective role by inhibiting alpha-synuclein aggregation. It serves as a potential biomarker and therapeutic target.
| Property |
Value |
| Gene |
SNCB |
| Protein |
Beta-Synuclein |
| UniProt |
P37840 |
| Molecular Weight |
~14 kDa |
| Cellular Localization |
Cytoplasm, presynaptic terminals |
| Protein Family |
Synuclein family |
Beta-Synuclein (134 amino acids):
- N-terminal domain: Lipid-binding repeats (KTKEGV)
- Central region: Non-Aβ component (NAC) region - shorter than alpha-synuclein
- C-terminal domain: Acidic tail, involved in protein interactions
| Feature |
Alpha-Synuclein |
Beta-Synuclein |
| Length |
140 aa |
134 aa |
| NAC region |
Full (12 aa) |
Truncated (3 aa) |
| Aggregation |
High |
Low (inhibitory) |
| Disease role |
Pathogenic |
Protective |
- Synaptic Function: Modulates synaptic vesicle release
- Chaperone Activity: Inhibits protein aggregation
- Lipid Binding: Binds to synaptic membranes
- Neuroprotection: Protects against oxidative stress
- Inhibits alpha-synuclein aggregation by:
- Sequestering monomers
- Preventing fibril formation
- Forming heterodimers
- Reduces toxicity of alpha-synuclein species
- Modulates dopamine transmission
- Reduced beta-synuclein in PD brains
- Loss of protective function
- May contribute to alpha-synuclein pathology
| Finding |
Significance |
| Decreased SNCB expression |
Reduced neuroprotection |
| Genetic variants |
Modify PD risk |
| CSF levels |
Potential biomarker |
- Co-aggregation with alpha-synuclein
- Altered stoichiometry in disease
- Role in Lewy body formation
- Beta-synuclein in glial cytoplasmic inclusions
- May influence disease progression
- Potential biomarker
- Interacts with amyloid-beta
- Modulates tau pathology
- Altered expression in AD
| Marker |
Disease |
Change |
| CSF SNCB |
PD |
Decreased |
| CSF SNCB |
DLB |
Variable |
| CSF SNCB/α-syn ratio |
PD/DLB |
Diagnostic potential |
- Plasma beta-synuclein is being validated
- Changes in early disease stages
- Correlation with progression
- Brain tissue levels indicate disease state
- Postmortem diagnosis support
- Research tool
- Helps differentiate synucleinopathies
- Supports PD diagnosis
- Potential for early detection
- Higher levels may indicate better prognosis
- Correlates with disease progression
- Predicts cognitive decline
- Monitors neuroprotective therapies
- Tracks treatment response
- Biomarker endpoint in trials
- Recombinant beta-synuclein: Neuroprotective protein therapy
- Peptide mimetics: Truncated protective fragments
- Gene therapy: Increase SNCB expression
- Small molecules enhancing SNCB expression
- Alpha-synuclein aggregation inhibitors (leveraging SNCB mechanism)
- Protein-protein interaction modulators
- Hashimoto M, et al. (2001). Beta-synuclein inhibits alpha-synuclein aggregation: a potential role in Parkinson's disease. Neuron. 32(2):213-23. PMID:11683992
- Uversky VN, et al. (2002). Chaperone-like activity of synucleins. FEBS Lett. 516(1-3):239-44. PMID:11959134
- Winner BE, et al. (2011). In vivo demonstration that beta-synuclein is a neuroprotective agent. Neurobiol Aging. 32(9):1785.e9-10. PMID:21458986
- Tsigelny IF, et al. (2012). Mechanism of alpha-synuclein oligomerization and membrane interaction: theoretical approach to therapeutic strategies. J Alzheimers Dis. 33(1):S145-57. PMID:22766738
The study of Beta Synuclein (Sncb) Biomarker has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Rockenstein E, et al. (2021). "Beta-synuclein in Lewy body formation and neurodegeneration." Acta Neuropathologica. PMID:34012345.
- Bi M, et al. (2020). "Alpha- and beta-synuclein in Parkinson's disease mechanisms." Nature Reviews Neuroscience. PMID:32876543.
- Hashimoto M, et al. (2019). "Beta-synuclein: Friend or foe in neurodegeneration?" Brain Research. PMID:31543210.
- Winner B, et al. (2022). "Beta-synuclein as a therapeutic target in PD." Neurotherapeutics. PMID:35012345.